Israel Englander’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.3M Buy
+61,400
New +$13.4M ﹤0.01% 2166
2025
Q1
– Sell
-118,800
Closed -$10.1M – 5847
2024
Q4
$10.1M Buy
118,800
+86,400
+267% +$7.95M ﹤0.01% 2173
2024
Q3
$2.91M Buy
+32,400
New +$2.83M ﹤0.01% 3348
2024
Q2
– Sell
-12,100
Closed -$966K – 5873
2024
Q1
$966K Sell
12,100
-9,100
-43% -$764K ﹤0.01% 4324
2023
Q4
$1.69M Buy
21,200
+17,200
+430% +$1.15M ﹤0.01% 3747
2023
Q3
$280K Sell
4,000
-200
-5% -$15K ﹤0.01% 4968
2023
Q2
$302K Buy
+4,200
New +$310K ﹤0.01% 4881
2021
Q4
– Sell
-293,900
Closed -$9.7M – 6775
2021
Q3
$9.7M Buy
+293,900
New +$11.5M 0.01% 2094
2021
Q2
– Sell
-25,000
Closed -$1.42M – 6516
2021
Q1
$1.42M Buy
25,000
+16,000
+178% +$1.13M ﹤0.01% 3854
2020
Q4
$733K Buy
+9,000
New +$673K ﹤0.01% 3935
2020
Q1
– Sell
-50,000
Closed -$5.17M – 3830
2019
Q4
$5.17M Buy
+50,000
New +$2.02M 0.01% 1899
2019
Q2
– Sell
-179,500
Closed -$2.55M – 4043
2019
Q1
$2.55M Buy
+179,500
New +$1.67M ﹤0.01% 2246

Other funds holding AXSM

Israel Englander's AXSM Position: Q3 2026 in Review

Israel Englander increased its Axsome Therapeutics (AXSM) stake by 138% in Q3 2026, buying an estimated $167M and bringing the position to 1,323,032 shares worth $244M. The position accounts for 0.08% of the portfolio, ranked #205.

Israel Englander first reported a position in AXSM in Q4 2015 and has held it in 37 quarters since. 466 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Israel Englander held 1,323,032 shares of Axsome Therapeutics worth $244M as of Q3 2026.
  • Israel Englander bought 766,944 Axsome Therapeutics shares in Q3 2026, an estimated $167M.
  • Axsome Therapeutics made up 0.08% of Israel Englander's portfolio in Q3 2026, its #205 holding.
  • Israel Englander first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 37 quarters since.
  • 466 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.